149 related articles for article (PubMed ID: 25026175)
21. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
[TBL] [Abstract][Full Text] [Related]
22. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
23. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
24. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
Lin YL; Xie PG; Ma JG
Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
[TBL] [Abstract][Full Text] [Related]
25. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
26. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
27. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
28. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
29. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
[TBL] [Abstract][Full Text] [Related]
30. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes.
Ryk C; Koskela LR; Thiel T; Wiklund NP; Steineck G; Schumacher MC; de Verdier PJ
Redox Biol; 2015 Dec; 6():272-277. PubMed ID: 26298202
[TBL] [Abstract][Full Text] [Related]
31. Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx.
Lu Z; Sturgis EM; Zhu L; Zhang H; Tao Y; Wei P; Wei Q; Li G
Mol Carcinog; 2018 Mar; 57(3):361-369. PubMed ID: 29073727
[TBL] [Abstract][Full Text] [Related]
32. Allelic deletions of cell growth regulators during progression of bladder cancer.
Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
[TBL] [Abstract][Full Text] [Related]
33. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Lykke MR; Nielsen TK; Ebbensgaard NA; Zieger K
Scand J Urol; 2015 Jun; 49(3):230-6. PubMed ID: 25731785
[TBL] [Abstract][Full Text] [Related]
34. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
35. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Seo SP; Kang HW; Kim WT; Lee JY; Ryu DH; Choi JW; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2019 Jun; 17(3):e704-e711. PubMed ID: 31088707
[TBL] [Abstract][Full Text] [Related]
36. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
[TBL] [Abstract][Full Text] [Related]
37. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
38. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
Deng S; He SY; Zhao P; Zhang P
World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
[TBL] [Abstract][Full Text] [Related]
39. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
40. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
